Update on Ablation for Barrett’s Esophagus
Endoscopic ablation has dramatically changed the treatment algorithm for patients with Barrett’s esophagus. Studies clearly show the benefits of this approach for patients with high-grade dysplasia and intramucosal carcinoma. Recent studies also provide evidence in support of this approach for patients with low-grade dysplasia but not for patients with nondysplastic Barrett’s epithelium. Endoscopic ablation is safe and efficacious in most but not all patients and disease progression may occur during initial therapy as well as after successful completion in a small difficult to identify subset of patients. Furthermore, the past year has provided us with a better understanding of the durability of endoscopic ablation with highly variable rates of disease recurrence. Studies are underway to help determine predictors of response and recurrence.
KeywordsBarrett’s esophagus Esophageal adenocarcinoma Dysplasia Radiofrequency ablation Endoscopic mucosal resection Cryotherapy
Compliance with Ethics Guidelines
Conflict of Interest
Gary Falk has consulted for and received travel/accommodation expenses from Aptalis Pharma, Olympus and CDX.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by the author.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.••Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–46. This international consensus provides evidence-based recommendations for the management of patients with high-grade dysplasia and intramucosal adenocarcinoma.CrossRefPubMedGoogle Scholar
- 6.Phoa KY, van Vilsteren FG, Pouw RE, Weusten BL, Schoon EJ, Bisschops R, et al. Radiofrequency Ablation in Barrett's Esophagus With Confirmed Low-Grade Dysplasia: Interim Results of a European Multicenter Randomized Controlled Trial (SURF). Gastroenterology. 2013;144:S-187.Google Scholar
- 14.van Vilsteren FG, Phoa KN, Alvarez Herrero L, Pouw RE, Sondermeijer CM, van Lijnschoten I, et al. Circumferential balloon-based radiofrequency ablation of Barrett's esophagus with dysplasia can be simplified, yet efficacy maintained, by omitting the cleaning phase. Clin Gastroenterol Hepatol. 2013;11:491–8.CrossRefPubMedGoogle Scholar
- 17.••Orman ES, Li N, Shaheen NJ. Efficacy and Durability of Radiofrequency Ablation for Barrett's Esophagus: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245–55. This systemic review and meta-analysis provides well-done summary estimates of the initial efficacy of radiofrequency ablation, long-term durability, and complication rates, albeit with considerable study heterogeneity.CrossRefPubMedGoogle Scholar
- 18.••Gupta M, Iyer PG, Lutzke L, Gorospe EC, Abrams JA, Falk GW, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology. 2013;145:79–86. This large multicenter consortium cohort study shows that compete eradication of intestinal metaplasia and dysplasia takes considerably longer than initially thought, and that recurrence of intestinal metaplasia occurs at a high rate.CrossRefPubMedGoogle Scholar
- 19.••Haidry RJ, Dunn JM, Butt MA, Burnell MG, Gupta A, Green S, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology. 2013;145:87–95. This large study of the British experience with radiofrequency ablation demonstrates a dysplasia clearance rate of 81 % at 1 year.CrossRefPubMedGoogle Scholar
- 25.••Phoa KN, Pouw RE, van Vilsteren FG, Sondermeijer CM, Ten Kate FJ, Visser M, et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology. 2013;145:96–104. Follow-up of 54 patients in the Netherlands demonstrates a sustained remission rate of high-grade dysplasia and intramucosal cancer of 90 % at 5 years.CrossRefPubMedGoogle Scholar
- 28.••Jovov B, Shaheen NJ, Orlando GS, Djukic Z, Orlando RC. Defective barrier function in neosquamous epithelium. Am J Gastroenterol. 2013;108:386–91. Ex-vivo studies of neosquamous Barrett’s epithelium demonstrates dilated intracellular space and increased permeability when compared to native squamous epithelium.CrossRefPubMedGoogle Scholar
- 31.Krishnan K, Pandolfino JE, Kahrilas PJ, Keefer L, Boris L, Komanduri S. Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology. 2012;143:576–81.CrossRefPubMedCentralPubMedGoogle Scholar
- 32.van Vilsteren FG, Alvarez Herrero L, Pouw RE, Schrijnders D, Sondermeijer CM, Bisschops R, et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study. Endoscopy. 2013;45:516–25.CrossRefPubMedGoogle Scholar